Imunon, Inc. Files 8-K on Executive Changes and Financials
Ticker: IMNN · Form: 8-K · Filed: Feb 10, 2025 · CIK: 749647
Sentiment: neutral
Topics: executive-changes, filing, financials
TL;DR
Imunon filed an 8-K detailing exec changes and financials - watch for updates.
AI Summary
Imunon, Inc. filed an 8-K on February 10, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also covers Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Celsion Corp, is incorporated in Delaware and based in Lawrenceville, NJ.
Why It Matters
This filing provides updates on key personnel changes and financial reporting, which can impact investor confidence and the company's strategic direction.
Risk Assessment
Risk Level: medium — The filing concerns executive and director changes, which can signal shifts in company strategy or internal dynamics, warranting investor attention.
Key Players & Entities
- Imunon, Inc. (company) — Registrant
- Celsion Corp (company) — Former company name
- February 9, 2025 (date) — Earliest event reported date
- February 10, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Lawrenceville, NJ (location) — Business address
FAQ
What specific changes were made regarding directors or officers?
The filing indicates events related to the departure of directors or certain officers, election of directors, and appointment of certain officers.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated February 9, 2025.
What is Imunon, Inc.'s former company name?
Imunon, Inc. was formerly known as Celsion Corp.
In which state is Imunon, Inc. incorporated?
Imunon, Inc. is incorporated in Delaware.
What are the main items covered in this 8-K filing?
This 8-K covers departure/election/appointment of officers and directors, compensatory arrangements, Regulation FD Disclosure, and Financial Statements and Exhibits.
Filing Stats: 1,298 words · 5 min read · ~4 pages · Grade level 12.2 · Accepted 2025-02-10 08:10:37
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share IMNN Nasdaq Capital Mark
- $480,000 — ill pay Dr. Faller an initial salary of $480,000 and a targeted annual performance bonus
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex10-1.htm (EX-10.1) — 1KB
- ex99-1.htm (EX-99.1) — 21KB
- ex10-1_001.jpg (GRAPHIC) — 1241KB
- ex10-1_002.jpg (GRAPHIC) — 807KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-25-005536.txt ( ) — 3073KB
- imnn-20250209.xsd (EX-101.SCH) — 3KB
- imnn-20250209_lab.xml (EX-101.LAB) — 33KB
- imnn-20250209_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Offer Letter of Employment between Imunon, Inc. and Douglas Faller 99.1 Press Release of Imunon, Inc., dated February 10, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMUNON, INC. Dated: February 10, 2025 By: /s/ Susan Eylward Susan Eylward General Counsel and Corporate Secretary